Japan’s Takeda has signed a deal to commercialize Teva’s innovative treatment for Parkinson’s disease, rasagiline, for use in Japan. It follows Takeda’s deal in Dec 2013 to develop Teva’s glatiramer acetate for the treatment of multiple sclerosis.
http://www.globes.co.il/en/article-takeda-to-sell-teva-parkinsons-treatment-in-japan-1000934433